Updated Safety and Efficacy Findings of the Phase 3 DESTINY-Breast03 Study

Erika P. Hamilton, MD, discusses the important thing security and efficacy findings from the part 3 DESTINY-Breast03 research. Erika P. Hamilton, MD, lead investigator and director of the Breast and Gynecologic Cancer Research Program on the Sarah Cannon Research Institute/Tennessee Oncology, discusses the important thing security and efficacy findings from the part 3 DESTINY-Breast03 research …